Purpose Both beta thalassemia and restless legs syndrome (RLS) patients share some common pathophysiological characteristics related to iron handling. In the present study, the aim was to explore the prevalence of RLS as well as to explore potential association between the syndrome and various quality of life-related parameters in a sample of beta thalassemia patients. Methods One hundred fourteen (age 40 ± 11 yr, 59 M/55F) beta thalassemia patients participated in this cross-sectional descriptive study. Patients were screened for RLS based on the international RLS study group diagnostic criteria as well as a battery of validated questionnaires. Results The prevalence of RLS in this sample of beta thalassemia patients was zero. The quality of life score was low (78 ± 18). Iron levels were within normal range (191 ± 66 mcg/dL) while ferritin levels were high as expected (1836 ± 225 ng/dL).
Introduction
Beta thalassemia is a group of hereditary blood disorders characterized by reduced or absent synthesis of the beta chains of hemoglobin and anemia and leading therefore to unaffected erythropoiesis [1] . Individuals with thalassemia major usually present within the first 2 years of life with severe anemia, requiring regular red blood cell transfusions. Regular transfusion therapy leads, among others, to iron overload-related complications. On the other hand, compliance with iron therapy mainly influences frequency and severity of the iron overload-related complications [2] .
Restless legs syndrome (RLS) (called also as WillisEkbom disease, WED) is a sensorimotor neurological disorder related to dopaminergic pathways while the neuronal iron handling have been implicated in the pathophysiology of the syndrome [3] . RLS is characterized by an uncontrolled need to move the extremities accompanied by unpleasant sensations especially during rest hours and at night, leading to severe sleep disturbance [4, 5] . RLS is categorized as either primary or secondary depending on the genetic or disease-induced nature of the cause [6, 7] . RLS susceptibility is strongly related to iron levels; however, iron-related genes do not seem to affect serum iron parameters while the correlation between RLS and iron parameters in serum seems to be weaker than assumed [8] . Peripheral iron deficiency with or without anemia appears to be an important environmental trigger of RLS symptoms [9] . Studies carried out in populations with iron deficiency anemia report approximately 35% with RLS symptoms [10] compared to the general population prevalence of 5% [11] . Recent studies have shown that IV iron therapy offers a rapid solution to replenishing body iron stores and diminishes or eliminates RLS symptoms in those with comorbid iron deficiency anemia [9] . However, many studies have shown that the local brain iron levels seem to be more important than the serum levels for the development of RLS [12, 13] . Low brain iron levels or deficiency has been found in patients with hemochromatosis indicating a possible role of local brain iron deficiency in the pathophysiology of RLS and PLMS, even in patients with systemic iron overload, such as in patients with hemochromatosis [14] . On the other hand, patients with beta thalassemia seem to have increased brain iron levels in the basal ganglia (striatum), thalamus, and adenohypophysis but not in the midbrain (red nucleus) [15] .
So far, there are no published reports to support the notion that beta thalassemia patients will follow the example of hemochromatosis patients showing evidence of RLS. It is not clear whether iron overload-related complications often seen in beta thalassemia patients will include the development or absence of RLS. Therefore, the primary aim of the current study was to examine the prevalence of RLS in this sample of beta thalassemia patients in central Greece where the prevalence of RLS has been assessed recently [16] . Taking into account the association and presence of RLS in other conditions characterized by iron overload, we expected to observe fewer cases of RLS in the examined sample of beta thalassemia patients. Secondary aims were to investigate potential associations-if any-of RLS with quality of life levels, sleep quality, daily sleepiness, fatigue, and depression levels.
Materials and methods

Participants
From May of 2012 to May of 2013, a total of 114 patients (54 female) were recruited from the thalassemia units of the Hospitals of Larissa, Trikala, and Karditsa, Greece. Patients were screened for RLS by an expert neurologist (GMH) based on the four international RLS study group diagnostic criteria [4] while the severity of RLS symptoms was evaluated using the IRLSSG severity scale [17] .
The inclusion criteria for this study were participants with beta thalassemia aged between 18 and 70 years and with clinical stable condition. Exclusion criteria included diagnosed neuropathies or reasons for being in a catabolic state within 3 months prior to the start of the study.
All patients gave their written informed consent prior to study participation. The study was approved by the Ethics Committee of the University of Thessaly (29/03/2012-519), Greece and the associated hospitals.
Biochemical assessment
Hematological and biochemical indices included the levels of hemoglobin, hematocrit, glucose, urea, creatinine, serum glutamic oxaloacetic transaminase (SGOT), albumin, total cholesterol, triglycerides, high-density lipoprotein (HDL), lowdensity lipoprotein (LDL), C-reactive protein (CRP), ferritin, iron, potassium, and phosphorus. The biochemical analysis was performed at the clinical labs of the Hospitals of Trikala, Larissa, and Karditsa under standard hospital procedures.
Questionnaires
All questionnaires were completed with the interview method by experienced personnel. We should note that all the questionnaires used in the current study have been used before in various RLS studies [18, 19] .
Fatigue levels were assessed using the fatigue severity scale (FSS) [20] . The patients' depression levels were evaluated by using a questionnaire developed by Zung [21] .Τhe Epworth sleepiness scale (ESS) was used to assess the daily sleepiness level of the patients [22] . Patient's quality of sleep was evaluated using a weekly sleep diary. This diary is adapted from the University of Massachusetts Medical School website.
Finally, the patient's subjective QoL outcomes were evaluated by using a Short Form-36 Health Survey (SF-36) version modified for patients receiving HD therapy [23] . Data are presented in Tables 1 and 2 .
Statistical analysis
Descriptive statistics and analysis of the data was carried out using the SPSS version 18 software and the level for statistical significance was set at P < 0.05.Normality of data was assessed using the Kolmogorov-Smirnov test.
Results
The patients' characteristics are presented in Table 1 . No patients with RLS or conditions mimicking RLS were found in the current study. Since no RLS-positive patients were found, the IRLS severity scale was not evaluated in any of the participants. As it was expected due to the nature of their disease, the patients present low hematocrit and hemoglobin levels, low HDL, and increased ferritin levels. The data derived by the various questionnaires are presented in Table 2 .
Discussion
To our surprise, no presence of RLS in this sample of patients with beta thalassemia was detected. We believe that the adequate levels of iron and ferritin which observed in the current study and the indication from other studies that beta thalassemia patients have higher levels of iron in the brain could be the reason of the absence of RLS symptoms [15] .
Beta thalassemia is a hereditary blood disorder and is particularly prevalent among people living in Mediterranean countries, including Greece. The prevalence of beta thalassemia in Greece is 0.04% while RLS is affecting the 3.9% of the Greek general population [16] and the 27% of the Greek hemodialysis patients [24] .
According to the most accepted hypothesis, the pathophysiology of RLS is centered on dopaminergic dysfunction in the central nervous system [25] . In addition, there is evidence to suggest that defect in the brain iron metabolism may contribute to the pathogenesis of the disease [25] . Iron is a cofactor for tyrosine hydroxylase, which is a rate-limiting step in the conversion of levodopa to dopamine [26] . In animals, iron deficiency anemia is associated with D2 receptor hypofunction and should be treated with iron therapy. In addition, RLS severity reported to worsen in patients with low ferritin levels [25] . It is noteworthy that published data reveal that treatment with intravenous iron could successfully ameliorate the RLS symptoms both in primary and secondary RLS patients [27] .
Patients with beta thalassemia have increased iron levels in blood serum [28] , in cerebrospinal fluid [29] , and in the brain while regular transfusion therapy could lead to iron overload with negative impact to overall health [30, 31] . Deposition of iron in the brain can contribute to the formation of free radicals, leading to lipid peroxidation and neurotoxicity [32] . Iron deposition in the central nervous system can occur in thalassemia, Parkinson's disease, and other diseases [31] . It was for that reason that we believed that RLS could be present in patients with beta thalassemia; however, the findings reject our original hypothesis as no RLS case was found in this sample of beta thalassemia patients in Greece.
Various physiological mechanisms could explain at least in part the lack of RLS symptoms in this group of patients. It seems that neurotoxicity which can be present in patients with thalassemia does not influence the dopaminergic system of the brain which is may be responsible for idiopathic RLS [25] . In addition, we did not examine the brain iron levels, which has been found to be increased in various part of the brain and it is considered to be another possible pathophysiological pathway responsible for RLS [15, 25] . The high ferritin value of the patients may also lead to the no RLS symptoms presence in our sample. Those levels are explained due to increased iron absorption from the gastrointestinal system and also because of the overload of the patients due to frequent transfusions.
Some limitations in the current study need to be acknowledged. The lack of control group seems to be a major pitfall. In the original design, it will have included as a control group all RLS-negative patients; however, in the case of negative findings (0% RLS prevalence), this is less of importance.
In conclusion, the data of the present study reveal no RLS cases in this sample of beta thalassemia patients. One of the more direct possibilities to be explored is whether the iron overloading will result in no RLS prevalence in these patients and also if it could lead to the discovery of new treatment approaches.
